104 related articles for article (PubMed ID: 3858395)
1. [Evaluation of a monoclonal antibody (CA 19-9 system) in gastrointestinal disease--in comparison with CEA and IAP].
Furukawa M; Kozaka S; Kushibiki K; Ashida Y; Saito H; Yamamoto H; Furukawa T
Nihon Gan Chiryo Gakkai Shi; 1985 Feb; 20(1):25-30. PubMed ID: 3858395
[No Abstract] [Full Text] [Related]
2. [New monoclonal antibodies in the diagnosis of gastrointestinal cancers].
Heptner G; Domschke S; Domschke W
Internist (Berl); 1986 Nov; 27(11):723-8. PubMed ID: 2433247
[No Abstract] [Full Text] [Related]
3. [Clinical evaluation of CA 19-9 for the detection of malignant tumors--a comparison with CEA and IAP].
Furukawa M; Kazaka S; Kushibiki K; Ashida Y; Saito H; Yamamoto H; Furukawa T
Gan No Rinsho; 1984 Apr; 30(4):357-62. PubMed ID: 6587133
[TBL] [Abstract][Full Text] [Related]
4. [The tumor-associated antigen CA 19-9 in the differential diagnosis and course control of malignancies of the pancreas and the gastrointestinal tract].
Klapdor R; Greten H
Dtsch Med Wochenschr; 1984 Dec; 109(50):1935-9. PubMed ID: 6210188
[No Abstract] [Full Text] [Related]
5. [Monoclonal antibodies against tumor-associated antigens of the gastrointestinal tract. Experimental and clinical outlook].
Schmiegel WH; Kalthoff H
Dtsch Med Wochenschr; 1985 Dec; 110(50):1943-9. PubMed ID: 3908048
[No Abstract] [Full Text] [Related]
6. Monoclonal antibodies in the diagnosis and treatment of malignant conditions.
Allum WH; Macdonald F; Fielding JW
Surg Annu; 1986; 18():41-64. PubMed ID: 2417343
[No Abstract] [Full Text] [Related]
7. [Clinical significance of the circulating tumor-associated antigen CA 19-9 in cancers of the digestive tract].
Staab HJ; Hornung A; Anderer FA; Kieninger G
Dtsch Med Wochenschr; 1984 Jul; 109(30):1141-7. PubMed ID: 6204834
[TBL] [Abstract][Full Text] [Related]
8. [Gastrointestinal cancer antigen and carcinoembryonic antigen in chronic pancreatopathies and pancreatic tumors].
Piantino P; Cerchier A; Tappero GF; Pecchio F; Ghisetti V
Minerva Med; 1985 Jul; 76(28-29):1331-4. PubMed ID: 4022426
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of M43: a novel cancer-associated mucin epitope.
Goodgame R; Kiefe C; Rose E; Sutton F; Brown J; Alpert E
Cancer Res; 1993 Jun; 53(12):2803-9. PubMed ID: 7684947
[TBL] [Abstract][Full Text] [Related]
10. Induction of antigen-specific immune response with use of anti-idiotypic monoclonal antibodies to anti-carcinoembryonic antigen antibodies.
Tsujisaki M; Imai K; Tokuchi S; Hanzawa Y; Ishida T; Kitagawa H; Hinoda Y; Yachi A
Cancer Res; 1991 May; 51(10):2599-604. PubMed ID: 2021940
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies in gastrointestinal cancers.
Mitchell EP; Schlom J
Semin Oncol; 1988 Apr; 15(2):170-80. PubMed ID: 2453081
[TBL] [Abstract][Full Text] [Related]
12. [Comparative study of the role of CA 19-9, CA 72-4 and CEA tumor antigens in the diagnosis of pancreatic cancer and other gastrointestinal malignant diseases].
Czakó L; Takács T; Babarczy E; Dux L; Lonovics J
Orv Hetil; 1997 Nov; 138(47):2981-5. PubMed ID: 9432648
[TBL] [Abstract][Full Text] [Related]
13. [Clinical evaluation of the tumor marker CA 19-9 in comparison with carcinoembryonic antigen (CEA) in surgical pre- and postoperative diagnosis].
Lorenz M; Happ J; Hottenrott C; Maul FD; Baum RP; Hör G; Encke A
Nuklearmedizin; 1986 Feb; 25(1):9-14. PubMed ID: 3459133
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies against carcinoembryonic antigen (CEA) discriminate between CEA produced by gastrointestinal tumors and CEA produced by other tumors.
Catane R; Ben Yoseff R; Livni N; Rosenmann E; Eshhar Z
Nat Immun Cell Growth Regul; 1990; 9(3):203-8. PubMed ID: 2196460
[TBL] [Abstract][Full Text] [Related]
15. Induction of specific CTL by MAGE-3/CEA peptide-pulsed dendritic cells from HLA-A2/A24(+) gastrointestinal cancer patients.
Hao X; Shao Y; Ren X; Liu H; Xu Q; Li H; Zhang P; An X; Ren B
J Cancer Res Clin Oncol; 2002 Sep; 128(9):507-15. PubMed ID: 12242516
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of the T.A.T.I. marker with CEA and Ca 19-9 in neoplasms of the gastrointestinal system. Preliminary data].
Ricci E; Pecchio F; Rapellino M; Giaccone M; Adamo R; Boltri F; Oliaro A
Minerva Dietol Gastroenterol; 1988; 34(4):217-20. PubMed ID: 3247053
[No Abstract] [Full Text] [Related]
17. Role of 131I-labelled anti-CEA/CA 19-9 monoclonal antibodies in the diagnosis and follow-up of gastrointestinal tumors.
Giordano A; Rufini V; Campioni P; Vaccaro A; Troncone L
Int J Rad Appl Instrum B; 1989; 16(2):151. PubMed ID: 2715009
[No Abstract] [Full Text] [Related]
18. [Diagnostic value of CA 19-9 and CEA in gastrointestinal pathology].
Patai A; Héber S; Döbrönte Z; Kovács LG
Orv Hetil; 1992 May; 133(21):1301-4, 1307. PubMed ID: 1603581
[TBL] [Abstract][Full Text] [Related]
19. [Tumor markers in digestive oncology: present status of the topic and prospects for the future].
Desaive C
Rev Med Liege; 1987 Nov; 42(22):881-7. PubMed ID: 2447625
[No Abstract] [Full Text] [Related]
20. [Immunohistochemical evaluation of several tumor markers (CEA, ferritin, Ca) and their correlation with estro-progestin receptor state in neoplasms].
Forti E; Wolf D; Melia M
Pathologica; 1985; 77(1049):241-9. PubMed ID: 3913892
[No Abstract] [Full Text] [Related]
[Next] [New Search]
